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Increasing evidence suggests that toll-like receptors (TLRs) play an important role in cerebral ischemia-reperfusion
injury. The endogenous ligands released from ischemic neurons activate the TLR signaling pathway, resulting in the
production of a large number of inflammatory cytokines, thereby causing secondary inflammation damage following
cerebral ischemia. However, the preconditioning for minor cerebral ischemia or the preconditioning with TLR ligands
can reduce cerebral ischemic injury by regulating the TLR signaling pathway following ischemia in brain tissue
(mainly, the inhibition of the TLR4/NF-κB signaling pathway and the enhancement of the interferon regulatory
factor-dependent signaling), resulting in TLR ischemic tolerance. Additionally, recent studies found that postconditioning
with TLR ligands after cerebral ischemia can also reduce ischemic damage through the regulation of the TLR signaling
pathway, showing a significant therapeutic effect against cerebral ischemia. These studies suggest that the ischemic
tolerance mediated by TLRs can serve as an important target for the prevention and treatment of cerebral ischemia. On
the basis of describing the function and mechanism of TLRs in mediating cerebral ischemic damage, this review focuses
on the mechanisms of cerebral ischemic tolerance induced by the preconditioning and postconditioning of TLRs and
discusses the clinical application of TLRs for ischemic tolerance.
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Ischemic stroke, a current major disabling and killer
disease worldwide, is characterized by a high incidence,
morbidity, and disability rate. However, to date, only
r-tPA intravenous thrombolysis has been proven to be
an effective therapy [1]; other effective treatments are
still lacking. However, the narrow time window (3 to 4.5
h after onset) and the reperfusion damage after thromb-
olysis in r-tPA intravenous thrombolytic therapy severely
limit its clinical application. Therefore, studies of cerebral
ischemic injury in recent years have focused on revealing
and inducing the endogenous protective mechanism of
cerebral ischemic injury, improving the protective effect
against cerebral ischemia, and alleviating cerebral ischemic
injury. As far back as the 16th century, the toxicologist* Correspondence: weiduantmmu@gmail.com; yangqwmlys@hotmail.com
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stated.Paracelsus observed that ‘the dose makes the poison’. A
corollary is that subtoxic doses of cellular stress can lead
to the generation of a protective state, termed ‘precondi-
tioning’ [2]. Preconditioning is a procedure by which a
noxious stimulus near to but below the threshold of dam-
age is applied to the tissue. Shortly after preconditioning,
or after a delay, the organ develops resistance to, or toler-
ance of, the same stimulus or even different noxious stim-
uli given beyond the threshold of damage. Preconditioning
thereby protects against subsequent injury [3]. Such
endogenous modulators mediate the phenomenon of
ischemic tolerance, which was first identified in the
brain in the early 1990s and has been shown to have a
neuroprotective role in cerebral ischemia [4]. In recent
years, increasing evidence has suggested that toll-like
receptors (TLRs) mediate inflammatory cerebral ische-
mic injury and play an important role in the secondary
brain injury following cerebral ischemia [5-7]. Additionally,
preconditioning with TLR ligands reduces cerebral ische-
mic damage, leading to ischemic tolerance. Importantly,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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TLRs also reduces cerebral ischemia reperfusion damage;
therefore, TLR-mediated ischemic tolerance has an import-
ant transforming significance in the prevention and thera-
peutic targets of cerebral ischemic injury. On the basis of
describing the function and mechanism of TLRs in mediat-
ing cerebral ischemic damage, this review focuses on the
mechanisms of cerebral ischemic tolerance induced by
TLR preconditioning and postconditioning and discusses
the clinical application of TLR ischemic tolerance.
Introduction of TLRs and their signaling pathways
TLRs are a group of classic pattern recognition receptors
(PRRs) that can recognize the pathogen-associated mo-
lecular patterns (PAMPs) from pathogenic microorgan-
isms and injury-related damage-associated molecular
patterns (DAMPs) [8]. To date, 11 TLRs have been
found in humans, and 13 TLRs have been identified in
mice; TLR1 to TLR9 are common to both species [9].
TLR2 can recognize lipopeptides; it may form a hetero-
dimer with TLR1 to recognize trimerized lipopeptides
and with TLR6 to recognize dimerized lipopeptides [9].
TLR3 recognizes double-stranded viral RNA and poly-
cytidylic acid (poly-IC) and mediates the activation of
NF-κB and the type I interferon (IFN) signaling pathway
[10,11]. TLR4 recognizes lipopolysaccharide (LPS) as a
cell wall component of gram-negative bacteria [12]; TLR5
recognizes the flagellin component of bacterial flagella
and regulates the natural and acquired immunity of intes-
tinal bacteria [13-15]. TLR7 and its related TLRs sense
single-stranded viral RNA [16-18], and TLR9 recognizes
the CpG-DNA pattern and reacts with herpes viral DNA
[19-21]. TLR11 and TLR12 in mice associate to detect
bacterial components [8,22,23]. Furthermore, TLRs can
also recognize the endogenous molecules released by
damaged cells, suggesting that the innate immune in-
flammatory reaction can be activated by the endogenous
ligands released from damaged tissue in the absence of
foreign pathogens.
On the basis of a specific adapter, a TLR signal can be
conducted through a MyD88-dependent or MyD88-
independent signal. In general, except for TLR3, the
signals of all TLR family members are initiated by the
MyD88 protein and conducted through the MyD88-
dependent signaling pathway. TLR2 and TLR4 can bind
to MyD88 after successfully assembling with TIRAP/Mal,
and after binding to IL-1R-associated kinase (IRAK)-4,
MyD88 can activate other members of the IRAK family,
such as IRAK-1 and IRAK-2 [24]. Then, IRAKs and
MyD88 disassociate and react with the TNFR-associated
factor 6 (TRAF6). Together with an E2 ubiquitin-
conjugating enzyme complex comprising Ubc13 and
Uev1A, TRAF6 catalyzes the formation of a lysine 63
(K63)-linked polyubiquitin chain on TRAF6 itself aswell as the generation of an unconjugated free polyubi-
quitin chain [25]. A complex of TGF-b-activated kinase 1
(TAK1), TAK1-binding protein 1 (TAB1), TAB2, and
TAB3 is activated by MAP kinase 6. Subsequently, IKK-a,
IKK-b, and NF-κB form an IKK complex to phosphorylate
IκB, thereby freeing NF-κB to translocate into the nucleus
and activate the expression of the pro-inflammatory cyto-
kine genes. The activation of the MAP kinase cascade is
responsible for the formation of another transcription
factor complex, AP-1, which targets cytokine genes [26].
TLR3 recognizes dsRNA and binds to TIR-domain-
containing adapter-inducing interferon-β (TRIF). TLR4
triggers both MyD88- and TRIF-dependent signaling path-
ways. After the binding to TLR4 and TRAM, TRIF is acti-
vated. TRIF associates with TRAF3 and TRAF6 through
the TRAF-binding motifs present in its N-terminal portion
[26]. TRAF3 is the key factor to activate TANK-binding
kinase 1 (TBK1) and IKK-i [27,28]. TBK1 and IKK-α phos-
phorylate interferon regulatory factor (IRF)3 and IRF7;
when the dimer of IRF3 and IRF7 is translocated into the
nucleus, the induction of type I IFNs and the expression of
IFN-inducible genes occur. Additionally, TRAF6 and RIP1
activate NF-κB, which induces the production of the pro-
inflammatory cytokines [26].
TLR7 and TLR9 signaling induces the production of
type I IFNs in a MyD88-dependent manner, in addition
to NF-κB-dependent cytokines. MyD88 forms a complex
with IRAK-1, TRAF6, TRAF3, IKK-α, and IRF7, and
phosphorylated IRF7 translocates into the nucleus to ac-
tivate the expression of genes encoding type I IFNs [26].
Toll-like receptors and cerebral ischemic injury
Post-ischemic inflammation is an important patho-
physiological process in the development of ischemic
stroke, but excessive inflammation can promote neur-
onal apoptosis and aggravate neurological impairment
[29]. TLRs mediate the inflammatory response in im-
mune cells, suggesting that they also participate in medi-
ating the inflammation and the secondary brain injury
following ischemia. It is now clear that TLRs play an im-
portant role in cerebral ischemia [30]. Injured neurons
release endogenous DAMPs to activate TLRs and further
stimulate inflammatory cascades to induce secondary
injury [31]. However, the complex mechanism of TLR-
mediated neuronal injury and the exact role of TLRs
have not yet been fully clarified.
TLR2 and cerebral ischemic injury
Recent studies have shown that the expression of TLR2
mRNA in focal ischemic brain tissue was significantly
increased, and TLR2 was the most strongly upregulated
TLR [5,32]. Additionally, compared with wild-type mice,
the area of infarction in TLR2-deficient mice was signifi-
cantly reduced [32]. Moreover, in the ischemic brain
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TLR2/1 dimer and CD36 induced ischemic inflamma-
tion and tissue damage [33]. These results indicate that
TLR2 plays an important role in the inflammatory injury
that follows cerebral ischemia.
Recent studies have shown that, compared with a con-
trol group, the number of CD11b-positive cells was signifi-
cantly reduced, and there was a significant reduction in
the neuronal death rate in C57BL mice arterially injected
with a TLR2 antibody (clone T 2.5) 45 min after cerebral
ischemia [34]. In clinical observations, TLR2 expression in
the peripheral blood cells of patients with ischemic stroke
was significantly upregulated. The addition of the per-
ipheral blood from patients with stroke into mono-
nuclear cells and human umbilical cord vein endothelial
cells induced a significant inflammatory reaction, and
this reaction could be inhibited by a TLR2 antibody [6].
These results suggest that blocking the TLR2 signal can
alleviate cerebral ischemic inflammation, and TLR2 is
expected to serve as an important intervention target
for the treatment of cerebral ischemia.
However, one report showed that 24 h after cerebral
ischemia-reperfusion injury, the area of cerebral infarc-
tion in TLR2-knockout mice was increased. This study
indicated that TLR2 knockout did not inhibit NF-κB
activation; on the contrary, it inhibited the activation of
the PI3K/Akt signaling pathway, thereby aggravating the
cerebral injury caused by ischemia reperfusion [35]. The
exact reason for the difference between the above observed
results is not yet clear, but it may be associated with
differences in animal models, suture size, body weight,
ischemia-reperfusion time, and cerebral blood flow.
Recent studies have shown that, compared with wild-
type mice, TLR2 knockout reduced the proliferative cap-
acity of the microglia in ischemic brain tissue, reduced
the MCP-1 level, and decreased the accumulation of the
CD45+/CD11b+ cells at the site of cerebral ischemic
injury, leading to a worsened delay of cerebral ischemic
injury, which manifested as an expanded area of chronic
cerebral infarction [36]. These results further suggest that
the function of TLR2 in cerebral ischemia-reperfusion in-
jury awaits additional investigation, especially for its effect
on the cerebral infarction in the chronic stage.
TLR2 mRNA and proteins are expressed in the nerve
primitive cells (NPCs) in the embryo, neonatal mouse,
and adult mouse as well as in in vitro NPC cultures
[37,38]. The TLR2 ligand Pam3CSK4 or an endogenous
ligand of low molecular weight hyaluronic acid inhibits
the formation of neurospheres in vivo, showing that
TLR2 activation inhibits the proliferation of embryonic
NPCs [38]. In adult mice, a TLR2 defect impairs the re-
generation of hippocampal neurons, but TLR2 activation
did not damage NPC proliferation in adult mice [39].
These results suggest that TLR2 is involved in nerveregeneration and remodeling, but the effect of TLR2 on
the nerve regeneration and tissue repair with cerebral
ischemic injury requires further investigation.
TLR3, TLR9, and cerebral ischemic injury
After 2 h of middle cerebral artery occlusion (MCAO)
followed by reperfusion for 22 h, the volume of cerebral in-
farction in TLR3- or TLR9-deficient mice was not signifi-
cantly reduced, and there was no improvement in the
neurological score [40], suggesting that TLR3 or TLR9 had
no protective effect on MCAO-induced ischemic cerebral
damage. Additionally, clinical studies have also shown that
the expression of TLR3 or TLR9 in the peripheral blood of
patients with ischemic stroke did not correlate with the
neurologic impairment [41], which further suggests that
TLR3 and TLR9 are not directly involved in the regulation
of inflammatory injury of cerebral ischemic reperfusion
(I/R). However, it has been demonstrated that TLR3 signal-
ing can activate the NF-κB to produce pro-inflammatory
cytokines, and the TLR3-deficient mice showed reduced
production of inflammatory cytokines [42]. Moreover,
recent studies have also shown that TLR3 signaling in-
hibits hippocampal neurogenesis [43-45], which has
been ascribed to inflammation in the adult brain [46].
These results suggest that TLR3 signaling is harmful to
brain injury.
TLR4 and cerebral ischemic injury
TLR4 plays an important role in innate immunity and
the cerebral ischemic injury of the central nervous sys-
tem. Our previous studies showed that the infarction
area and the neurological impairment of the TLR4-
knockout mice in focal MCAO were significantly re-
duced [47]. Subsequently, the whole cerebral ischemia
model further confirmed that the cerebral ischemic
damage in TLR4-knockout mice was also significantly
reduced [7]. Similarly, the degeneration of retinal gan-
glion cells (RGCs) induced by ischemia and axotomy
could be reduced in TLR4-knockout mice, and the phos-
phorylation levels of ERK-1/-2, c-Jun N-terminal kinase
(JNK)-1/-1, and p38 were significantly decreased, with a
low level of inducible NO synthase [48]. In vitro experi-
ments showed that after oxygen-glucose deprivation
(ODG), the survival rate of cultured cortical neurons from
TLR4-knockout mice was significantly increased [49].
Additionally, spinal cord I/R injury also led to TLR4 up-
regulation and microglial activation, which initiates neuro-
inflammation and neuroapoptosis via the NF-κB/IL-1β
pathway [50]. Clinical studies have further confirmed that
the TLR4 expression in neutrophils was associated inde-
pendently with patients’ prognoses [51]. These results sug-
gest that TLR4 mediated the post-ischemic inflammation,
and the inhibition of TLR4 activation could significantly
reduce cell damage in vivo and in vitro.
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monocytes in the peripheral blood of patients with cere-
bral infarction was significantly increased, and the correl-
ation analysis showed that TLR4 expression and cytokine
levels were closely related to stroke severity [52]. Add-
itionally, after adding the serum of patients with cerebral
ischemia into the cultured monocytes and human umbil-
ical vein endothelial cells, a strong inflammatory response
occurred, which was blocked by the addition of a TLR4
antibody [6]. Moreover, inhibition of the TLR4/NF-κB
pathway decreased I/R brain and spinal cord injuries
[50,53]. These above results further suggest that TLR4 is
involved in the cerebral ischemic damage, suggesting that
TLR4 is expected to become an important intervention
target for cerebral ischemic damage.
The TLR signaling pathway has been shown to be in-
volved in the inflammatory response following cerebral
I/R, but the accompanying downstream TLR signaling
events remain poorly understood. Interestingly, the in-
farct sizes were not decreased in MyD88- or TRIF-mu-
tant mice compared to that in wild-type (WT) mice
following focal ischemia [54]. A recent study showed
that a compensatory Th2-type skew at baseline in
MyD88−/− mice and a paradoxical switch to a Th1
phenotype following focal cerebral ischemia; addition-
ally, the MyD88 pathway directs the expression of neu-
trophil chemoattractants following cerebral ischemia
[55]. In contrast, the MyD88-independent pathway and
the ubiquitin-mediated proteolysis pathway may be the
most vital molecules among TLR downstream pathways
in incidences of ischemic stroke [56]. Therefore, the ac-
companying downstream TLR signaling following ische-
mia needs to be further explored.
Studies have shown that TLR4 plays an important role
in NPC proliferation and differentiation. TLR4 is widely
expressed in the NPCs of embryos, neonatal mice, and
adult mice [39]; TLR4 defects can promote NPC prolif-
eration and differentiation [39]. Additionally, a TLR4 in-
hibitor increases NPC proliferation and differentiation
[39]. This result suggests that TLR4 signaling can nega-
tively regulate NPC proliferation and differentiation in
adult mice. However, a recent study showed that the
area of skin wounds in TLR4-/- mice was significantly
larger; meanwhile, the expression of TGF-b and CCL5
was reduced, indicating that TLR4 can regulate wound
healing by increasing TGF-b and CCL5 [57]. However,
in the context of cerebral ischemia, the effect of TLR4
activation by endogenous ligands on the regeneration of
nerve cells and tissue repair awaits further study.
TLR8 and cerebral ischemic injury
TLR8 is mainly expressed in cortical neurons. Studies
have shown that TLR8 expression was significantly
increased at 6 h after cerebral ischemia in mice, and inin vitro oxygen-glucose deprivation (OGD) in cells, the
expression levels of TLR8 and the downstream JNK
signaling pathway were also significantly upregulated
[58]. However, after the specific inhibition of TLR8 using
siRNA, the SH-SY5Y cells with OGD were significantly
protected. Additionally, TLR8 activation enhanced the
apoptotic and the inflammatory response after stroke
mediated by T cells [58]. The above results show that
TLR8 activation aggravated ischemic brain injury. Add-
itionally, clinical studies have shown that TLR8 expres-
sion in the peripheral blood of patients with ischemic
stroke significantly correlated with the prognosis of the
patients [41], which further demonstrates that TLR8 is
directly involved in the inflammatory damage of cerebral
ischemia and hypoxia.
Preconditioning with TLR ligands and cerebral ischemic
injury
Many studies support the idea that innate immunity has
a toxic effect in cerebral ischemic injury. As mentioned
previously, TLR2 and TLR4 knockout reduces inflamma-
tion, decreases the cerebral infarction area, and improves
the neurological function score in MCAO mice; there-
fore, targeting the TLR signal may become an important
treatment strategy for cerebral ischemic injury [59]. Re-
cent studies have found that a small dose of TLR ligand
before cerebral ischemia generated a tolerance for the
subsequent cerebral ischemic damage. For example, the
application of LPS (a powerful TLR4 agonist) as precon-
ditioning prior to cerebral ischemia reduced the subse-
quent cerebral ischemic injury and improved the
neurological function score [60], which was termed
LPS tolerance [61]. To date, it has been reported that
preconditioning with TLR2, 3, 4, 7, and 9 ligands in-
duces TLRs to generate ischemic tolerance and also re-
duces cerebral ischemic damage [62-66] (Table 1).
TLR2 ligand preconditioning and ischemic injury
Studies have shown that TLR2 induces ischemic tolerance
[62]. Systematic injection of the TLR2 ligand Pam3CSK4
24 h before the focal MCAO cerebral ischemia, the signi-
ficantly reduced volume of cerebral infarction in the
Pam3CSK4-preconditioning mice were observed, as well as
reduced brain edema, maintained nerve function, and re-
duced mortality in the acute phase [62]. It is important to
note that Pam3CSK4 preconditioning can reduce the
amount of serum globulin and maintain the function of
the blood-brain barrier after cerebral I/R injury [62]. These
results show that maintaining the function of the blood-
brain barrier may be one of the mechanisms of Pam3CSK4
preconditioning in protecting cerebral ischemia.
Additionally, the systematic injection of Pam3CSK4 1
h before the focal cerebral ischemia could also signifi-
cantly reduce cerebral ischemic-reperfusion injury [67].
Table 1 TLRs preconditionings and effects
Animal Model Preconditioning time/approach TLR/ischemia Result and mechanism Author Reference
Mice MCAO, 60-min ischemia, 24-h
reperfusion
72 h/12-min ischemia Ischemic
preconditioning
Decrease brain infarction volume, and IRF gene participate
in brain protection
Stevens SL [79]
Mice MCAO, 60-min ischemia, 6-h
reperfusion
24 h/IP TLR2, Pam3CSK4 Decrease brain infarction and edema, improve neurological
function, and maintain BBB function
Hua F [60]
Mice MCAO, 45-min ischemia, 24-h
reperfusion
72 h/subcutaneous injection TLR3, poly-ICLC Decrease brain infarction volume and improve neurological
function
Packard AEB [63]
Mice MCAO, 120-min ischemia, 22-h
reperfusion
24 h/systemic injection TLR3 poly-IC Decrease brain infarction volume and neurological defect and
lower the levels of TNF-α and IL-6 in
cortex and striatum
Pan LN [66]
Mice MCAO, 60-min ischemia, 24-h
reperfusion





MCAO, 120-min ischemia, 22-h
reperfusion
2, 3, 4 days/IV TLR4 LPS Decrease brain infarction volume, mediated by TNF-α Tasaki K [72]
Mice MCAO, 120-min ischemia, 47-h
reperfusion
48 h/IP TLR4 LPS Decrease brain infarction volume, inhibit the infiltration of
neutrophil and activation of the microglia
Rosenzweig HL [73]
Mice MCAO, 40-, 45-, 60-min ischemia,
24-h reperfusion
72 h/IP TLR4 LPS Decrease brain infarction volume that was mediated by IRF3 Marsh B [61]
Mice MCAO, 40-to 60-min ischemia,
24-h reperfusion
72 h/subcutaneous injection TLR4 LPS Decrease brain infarction volume, and TRIF-IRF3 play vital role Vartanian KB [58]
Mice MCAO, 60-min ischemia, 24-h
reperfusion
72 h/IP TLR4 Decrease brain infarction volume, and inhibit TNF-α signaling
pathway after cerebral ischemia
Rosenzweig HL [76]
Mice MCAO, 45-to 60-min ischemia,
23-h reperfusion
72 h/subcutaneous injection TLR7 GDQ Decrease brain infarction volume and neurological functional
score that was protected through I type interferon
Leung PY [62]
Mice MCAO, 60-min ischemia, 72-h
reperfusion
30 min/IV TLR8 R848 Increase neurological function defect and mortality, activate
pro-apoptotic JNK pathway and inflammation
Tang SC [56]
Mice MCAO, 60-min ischemia, 24-h
reperfusion
72 h/IP TLR9 CpG-ODN Decrease brain infarction volume and TNF-α play a vital role Stevens SL [64]
Mice MCAO, 60-min ischemia, 24-h
reperfusion
72 h/IP or subcutaneous injection TLR9 CpG-ODN Decrease brain infarction volume and IRF gene participate in
cerebral protection after ischemia
Stevens SL [79]
Mice MCAO, 60-min ischemia, 24-h
reperfusion
1 h/IP TLR9 CpG-ODN Decrease brain infarction and activation of PI3K/Akt signaling Lu C [78]
MCAO: middle cerebral artery occlusion; IP: intraperitoneal injection; IV: intravenous injection; HI: hypoxic-ischemic; ICA: internal carotid artery; IRF: interferon regulatory factor; TLR: toll-like receptor; BBB: blood-brain
barrier; Poly-IC: polycytidylic acid; Poly-ICLC: polyinosinic-polycytidylic acid; FADD: Fas-Associated protein with Death Domain; LPS: lipopolysaccharide; IRF: interferon regulatory factor; TRIF: TIR-domain-containing
adapter-inducing interferon-β; GDQ: gardiquimod; JNK: c-Jun N-terminal kinase; CpG-ODN: CpG-motif oligodeoxynucleotide. MCAO, 60-min ischemia, 24-h reperfusion: the mice was employed MCAO (cerebral ischemia)
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significantly reduced, whereas the expression levels of
Bcl-2, Hsp27, and Hsp70 were significantly increased.
Furthermore, the protective effect of Pam3CSK4
preconditioning was implemented mainly through the
TLR2/PI3K/Akt-dependent signaling pathway [67]. These
results suggest that the Pam3CSK4 preconditioning for
cerebral ischemic tolerance not only inhibits the inflam-
matory response but also plays a role in the anti-apoptotic
mechanism and the brain protection of Hsp (Figure 1C).
TLR3 ligand preconditioning and cerebral ischemic injury
TLR3 ligand poly-IC preconditioning has also been dem-
onstrated to induce ischemic tolerance [65]. The sub-
cutaneous injection of poly-IC to mice 3 days before
MCAO significantly reduced the infarction area, and this
effect was dose dependent; importantly, despite the fact
that the protective effect of poly-IC preconditioning was
similar to the LPS preconditioning, poly-IC showed no
significant toxicity [65]. Additionally, the systematic
injection of poly-IC to mice 2 h before MCAO also
reduced the cerebral infarction area and neurological
impairment [68]. Our study found that the intraperito-
neal injection of poly-IC 1 h before ischemia also had a
protective effect for cerebral ischemia (unpublished
data). These decreased cerebral I/R injury by poly-IC
treatment may be via the TLR3-mediated prevention ofFigure 1 Schematic of TLR signaling and gene expression following stroke
activation without IRF3 activation. (B) LPS (CpG) preconditioning prior to strok
increased Ship1, Tollip, and p105 lead to the suppression of NF-κB activity and
preconditioning activates the TLR2/PI3K/Akt signaling pathway and subseque
increases the expression of Bcl-2, Hsp27, and Hsp70. (D) Poly-IC preconditioni
activates IRF7 and induces IFN-α production. DAMPs, damage-associated mol
adapter-inducing interferon-β; IRF, interferon regulatory factor; LPS, lipopolysaFas/Fas-Associated protein with Death Domain (FADD)
interaction [69]. These results suggest that poly-IC pre-
conditioning can significantly reduce the focal cerebral
I/R injury. Poly-IC preconditioning also alleviated the
death of mixed cortical cells after OGD [65] and allevi-
ated OGD-induced astrocyte damage [68], indicating
that poly-IC preconditioning can reduce the ischemic
cell damage in vitro and has a protective effect on neu-
rons and glial cells.
Poly-IC preconditioning can induce IFN-β expression
in astrocytes and microglial cells of ischemic brain tissue
[70] and maintain the bypass transporter function of
endothelial cells to reduce the loss of transendothelial
electronic resistance [70]. Moreover, type I IFN signaling
in brain microvascular endothelial cells was required for
the cerebral ischemic protection, suggesting that the
protection of poly-IC preconditioning against cerebral
ischemia was achieved mainly by the type I IFN signaling
to maintain the blood-brain barrier. Additionally, poly-
IC preconditioning can activate the expression levels of
TRIF and IRF3 in the ischemic brain tissue and increase
the generation of IFN-β [68,71], which further supports
the protective effect of the TRIF-IRF signaling pathway
in cerebral ischemia (Figure 1D). However, poly-IC pre-
conditioning also significantly inhibited NF-κB activity
and the generation of the pro-inflammatory cytokines
TNF-α and IL-6 in the ischemic brain tissue and. (A) TLR4 signaling cascades following stroke. Stroke leads to NF-κB
e leads to robust activation of IRF3 and type I interferon; meanwhile, the
pro-inflammation cytokines compared to stroke alone. (C) Pam3CSK4
ntly downregulates NF-κB activity and the expression of Bax, as well as
ng activates IRF3 and induces IFN-β production. (E) GDQ preconditioning
ecular patterns; TLR, toll-like receptor; TRIF, TIR-domain-containing
ccharide; Poly-IC, polycytidylic acid; .
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poly-IC preconditioning on the pro-inflammatory reac-
tion cannot be excluded.
However, as discussed above, although TLR3 signaling
is harmful to brain injury, it has no direct toxic effects
in cerebral I/R injury. Thus, according to the precondi-
tioning concept, the pretreatment of TLR3 ligand poly-
IC, called TLR3 preconditioning, still elicits controversy.
Further research needs to be conducted to confirm this
concept of TLR3 preconditioning.
TLR4 ligand preconditioning and cerebral ischemic injury
The transient ischemic preexposure of brain tissue can
lead to a tolerance of the brain tissue for the subse-
quently severe cerebral ischemia [72]. Clinically, the
phenomenon of ischemic preconditioning tolerance has
also been observed, and the transient ischemic attack
could reduce the severity of the secondary ipsilateral
stroke. Interestingly, ischemic preconditioning induced
by 6 min of blockade in the bilateral carotid artery had a
protective effect on the cerebral ischemia of wild-type
mice; however, this protective effect disappeared in
TLR4-/- mice [73]. For the ischemic-preconditioning
mice, the levels of TNF-α, iNOS, and COX-2 in the
brain tissue were decreased, and this change was associ-
ated with TLR4-knockout mice [73]. These results show
that TLR4 preconditioning is involved in the protective
effect of ischemic preconditioning in the brain.
It has been reported that the activation of TLR4 by a
small dose of LPS preconditioning could significantly re-
duce the severity of the damage in subsequent ischemic
stroke. First, it was found that ischemic tolerance was
induced in spontaneously hypertensive rats (SHR) by the
injection of a single dose of LPS (0.9 mg/kg, i.v.) 1 to 7
days prior to the permanent MCAO [74]. Subsequently, it
was found that in the mice treated with LPS (0.2 mg/kg)
48 h before ischemia induced by transient MCAO, LPS
preconditioning induced significant neuroprotection
against MCAO [75]. In a neonatal pig model of brain
injury induced by cardiac arrest in hypothermia, LPS
preconditioning induced robust protection against brain
injury resulting from deep hypothermic circulatory
arrest [76]. Recent studies have found that LPS precondi-
tioning can also reduce brain damage in a neonatal HI rat
model [77]. These results indicate that LPS precondition-
ing can induce a strong protective effect of cerebral ische-
mia for both permanent and transient cerebral ischemia
models. Additionally, LPS preconditioning alleviates cere-
bral ischemic damage in adult rats, neonatal rats, mice,
and neonatal piglets. Therefore, under the premise of a
suitable dosage, LPS preconditioning provides a promising
opportunity to prevent cerebral ischemic damage.
However, the exact molecular mechanism of ischemic
tolerance induced by TLR4 activation with a non-lethaldose of LPS is unclear. It has been reported that TNF-α
plays an important role in the ischemic tolerance in
mice induced by LPS preconditioning [78]. LPS precon-
ditioning significantly increased the level of TNF-α in
blood prior to stroke, and TNF-α-deficient mice could not
generate a protective effect of cerebral ischemia induced
by LPS preconditioning. Additionally, the beneficial effect
of LPS preconditioning in SHR was completely nullified
by concurrent administration of TNFbp. The above results
suggest that the tolerance to ischemia induced by LPS is
likely to be mediated by TNF-α [78].
The inhibition of excessive inflammation of cerebral
ischemia is a distinctive feature of LPS preconditioning.
LPS preconditioning inhibits the neutrophil infiltration
of the brain tissue and the activation of microglia sur-
rounding the ischemic brain tissue, which are simultan-
eous with the inhibition of the mononuclear cells in
peripheral blood [75]. Another study showed that the
LPS stimulation in MCPIP1-deficient mice significantly
increased the volume of cerebral infarction, accompan-
ied by a significant upregulation of the pro-inflammatory
cytokines in ischemic brain tissue, indicating that the
protective effect of LPS preconditioning against cerebral
ischemia was generated through the reduced level of
pro-inflammatory cytokines by MCPIP1 [79]. Addition-
ally, in the neonatal rat model of cerebral ischemia and
hypoxia, LPS preconditioning upregulated the expres-
sion of eNOS in neurons and vascular endothelial cells
by activating Akt, resulting in a protective effect against
cerebral ischemia [77].
Genomic promoter analysis showed that 24 h after
stroke, the expression levels of type I interferon in brain
tissue were significantly increased in the mice with LPS
preconditioning, as confirmed by the PCR assays [63].
TRIF activation after stroke can reduce the death rate of
cortical neurons after OGD. In the focal MCAO model,
the protective effect of LPS preconditioning against
cerebral ischemia was dependent on the TLR4 signal
transduction via TRIF. Additionally, IRF3-deficient mice
could not produce a protective effect against cerebral
ischemia [60,63]. These results indicate that IRF3 plays
an important role in the protective effect of TLR4 acti-
vation by LPS preconditioning against cerebral ische-
mia, and LPS preconditioning alters the TLR signaling
pathway after stroke and has a protective effect against
cerebral ischemia mainly through the TRIF/IRF3 signal-
ing pathway (Figure 1B).
TLR7 ligand preconditioning and cerebral ischemic injury
A recent study has shown that gardiquimod (GDQ)
preconditioning of TLR7 ligand can also have a strong
protective effect on the subsequent cerebral ischemia. At
72 h before MCAO, the subcutaneous injection of TLR7
ligand GDQ to mice significantly reduced the area of
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[64]. In GDQ-pretreated mice, the transcription levels of
five IFN-related genes, including Usp18, Oasl2, Isg15,
and Ifit1, were significantly increased, indicating that
GDQ preconditioning could change the gene response
to stroke in mice, and the signaling of type I interferon
plays an important role in the protection of cerebral is-
chemia by GDQ preconditioning. Additionally, com-
pared with type I IFN (IFNAR)+/+ mice, the protective
effect of cerebral ischemia in IFNAR-/- mice with GDQ
preconditioning was significantly decreased [64], indicat-
ing that TLR7 mediates the protection of cerebral ische-
mia through its cognate receptor IFNAR. Interestingly,
GDQ preconditioning provided robust neuroprotection
in TNF-/- mice, indicating that TNF-α was not essential
for protection. However, TNF-α is necessary for the ische-
mic tolerance induced by LPS and cytosine-phosphate-
guanine (CpG) preconditioning (Figure 1E).
TLR8 ligand preconditioning and cerebral ischemic injury
Recently, it has been reported that the femoral venous in-
jection of the TLR8 ligand R848 (1 mg/kg) 30 min prior to
the MCAO in a mouse model could not produce the pro-
tective effect on cerebral ischemic damage in mice [58].
The reason may be related to the increasing infiltration of
T cells and the apoptosis of neurons in the ipsilateral brain
tissue after cerebral ischemia-reperfusion injury [58]; how-
ever, the exact cellular and molecular mechanism is not
fully understood. Additionally, the effect of R848 precon-
ditioning on the cerebral ischemia-reperfusion injury
needs to be further verified, such as the optimization of
the time point, the approach, and the R848 dosage.
TLR9 ligand preconditioning and cerebral ischemic injury
Studies have shown that TLR9 can cause ischemic toler-
ance [66]. The systematic injection of the TLR9 ligand
CpG prior to cerebral ischemia reduced the cerebral is-
chemic damage by up to 60%, and the degree of this
protection was dose dependent. Moreover, CpG precon-
ditioning can produce the same protective effect on the
cells in vitro. Additionally, the CpG-motif oligodeoxynu-
cleotide (CpG-ODN) pretreatment has been shown to
induce protection against cerebral I/R injury via the acti-
vation of PI3K/Akt signaling [80]. CpG preconditioning
significantly increased the level of TNF-α in the serum
of mice prior to MCAO, and TNF-α was essential to the
subsequent protective effect of the brain because CpG
preconditioning in TNF-α-knockout mice did not produce
the protective effect against cerebral ischemia [66]. These
results suggest that the protection against cerebral I/R
injury by CpG preconditioning of TLR9 ligand and LPS
preconditioning share a similar mechanism (Figure 1).
A recent study confirmed that the preconditioning of
TLR4 and TLR9 ligands can induce similar genomicchanges in brain tissue, mainly characterized by similar
changes in the TLR signaling pathway. Both ligands can
cause the transcription of IRF genes, thereby increasing
the expression of type I interferon [81]. A phase II clin-
ical trial of CpG-ODNs as an adjuvant drug and antitu-
mor therapy is ongoing [82]. Therefore, CpG-ODNs
may provide a good prospect for the prevention and
treatment of cerebral ischemia.
Mechanism of the protection against cerebral ischemia by
TLR preconditioning
The preexposure of brain tissue to transient ischemia
may cause tolerance to the subsequent severe ischemic
damage. A recent study found that transient ischemia
can induce subsequent changes in TLR signaling genes
in the ischemic brain tissue, mainly in the 13 genes
whose transcription is mediated by IRF. This change in
the genetic profile was not found after a stroke without
preconditioning [81]. These results suggest that TLR sig-
nals and IRFs play an important role in the cerebral tol-
erance induced by transient ischemia.
It had been found that the preexposure of LPS can in-
duce a state of low reactivity in cells for subsequent sec-
ondary LPS stimulation, known as endotoxin tolerance.
This state of low reactivity is related to the low expres-
sion of the LPS receptor complex TLR4/MD-2 on the
cell surface, the reduced formation of TLR4-MyD88
complex, and the subsequent impairment of IRAK-1 ac-
tivity [83]. The main characteristic of LPS-tolerant cells
is that TLR4 stimulation cannot produce TNF-α. Unlike
the primary cells, LPS-tolerant cells cannot recruit
MyD88 to TLR4 and therefore do not activate IRAK-1
and NF-κB [83]. After the preexposure to LPS, with a
precise negative feedback loop, the TLR4-NF-κB axis
does not operate normally. For example, TRIM30 imple-
mented the negative feedback regulation of the NF-κB
activation mediated by TLRs through the degradation of
TAB2 and TAB3 [84]. Additionally, enhancing Ship1 and
Tollip inhibit TLR signaling, which leads to the suppres-
sion of NF-κB activity [60,85]. Additionally, the p50 pre-
cursor protein p105, which inhibits NF-κB activity by
acting like an IκB molecule by sequestering NF-κB in
the cytosol [60]. Thus, the subsequent TLR4-NF-κB
signal was suppressed, and the production of pro-
inflammatory cytokine was significantly reduced, thereby
reducing the inflammatory response. The injection of a
small dose of LPS in mice prior to MCAO was also able
to generate tolerance to the subsequent cerebral ische-
mic damage, which was mainly dependent on the inhib-
ition of TLR4 and the activation of the downstream
signaling molecule NF-κB, thereby alleviating the inflam-
matory reaction of cerebral ischemia produced by this
pathway [86]. When cerebral ischemic injury occurs, the
endogenous ligands released from the damaged neurons
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ways, resulting in the production of a large number of
pro-inflammatory cytokines, and the activation of the
inflammatory response may aggravate cerebral ischemic
damage. However, the cellular pathways of TLR4 and
cytokines could be altered in the mice with LPS precon-
ditioning, which could suppress the immune response
by increasing signal-inhibiting substances and decoying
the receptors and anti-inflammatory cytokines. Thus, the
induced immune suppression would reduce inflammation
and the subsequent secondary cell death [60,86,87]. In
contrast, the re-exposure of LPS increased the activity of
the TLR4-IRF3 pathway, causing an increase in IFN-β
production [88]. Additionally, the protection of cerebral
ischemia induced by LPS preconditioning disappeared in
TRIF- and IRF-knockout mice [60,81]. These results
suggest that LPS preconditioning alters transcription in
cells, inhibits the production of TNF-α and other pro-
inflammatory factors induced by NF-κB, enhances the
level of IFN-β induced by IRF3, alleviates the secondary
inflammation after cerebral ischemia injury, and produces
ischemic tolerance (Figure 1B).
Similar to the tolerance of LPS, the CpG precondition-
ing on TLR9 ligands caused a low reactive state for the
subsequent CpG stimulation [89]. Moreover, TLR cross-
tolerance can be generated between two TLRs because
CpG preconditioning on TLR9 ligands can cause toler-
ance to the subsequent LPS stimulation of TLR4 [89,90].
LPS stimulation after CpG preconditioning on the cells
would not only reduce TNF-α generation but also in-
crease IFN-β generation [89]. After CpG precondition-
ing, the volume of cerebral infarction in mice was
significantly reduced, and the level of TNF-α in periph-
eral blood was increased. However, the CpG precondi-
tioning on TNF-α-/- mice did not show a significant
protective effect against cerebral ischemia, suggesting
that TNF-α is necessary for CpG-induced ischemic tol-
erance [66]. These results indicate that LPS and CpG
preconditioning share a common protection mechanism.
Additionally, the direct CpG preconditioning for the cul-
ture of mixed cortical cells can produce a protective ef-
fect on the subsequent mixed cortical cells with OGD.
CpG treatment may modulate the cytokine response to
injury in glial cells, which in turn may have a protective
effect on neurons. However, its mechanism has not yet
been fully elucidated [66].
TLR ligand postconditioning and cerebral ischemic injury
Recently, some studies have shown that the modifica-
tion of reperfusion after cerebral ischemia can produce
a protective effect against cerebral ischemia, and this
phenomenon is known as postconditioning. For in vivo
and in vitro models, postconditioning 10 min after the
ischemic reperfusion for 10 min achieved the greatestprotective effect, with the infarction area reduced by
50% and the cell death rate reduced by 30% [91]. The
level of protection of ischemic postconditioning against
cerebral ischemia is similar to that of the precondition-
ing; however, the mice that received both ischemic pre-
conditioning and postconditioning did not exhibit a
greater protective effect [91], indicating that the ischemic
preconditioning and postconditioning may share a similar
signaling mechanism. Recent studies have shown that
ischemic postconditioning of TLRs could also produce a
protective effect against cerebral ischemia by inducing the
TLR ischemic tolerance [67,69,80,92] (Table 2). This result
provides a new approach for the treatment of cerebral
ischemia.
TLR2, TLR9 ligand postconditioning and cerebral ischemic
injury
Intraperitoneal injection of TLR2 ligand Pam3CSK4 30
min after cerebral ischemia significantly reduced the in-
farction area [67]. Pam3CSK4 postconditioning increased
the levels of Hsp27, Hsp70, and Bcl2 in the ischemic
brain tissue and reduced Bax levels and NF-κB activity.
Importantly, compared with the control group, the
phosphorylation levels of Akt/Akt and GSK-3b/GSK-3b
in the Pam3CSK4 postconditioning group were signifi-
cantly increased, suggesting that the postconditioning of
TLR2 ligands alleviated the focal cerebral ischemic injury
mainly through a TLR2/PI3K/Akt-dependent mechanism.
It has also been demonstrated that the administration of
TLR9 ligand CpG-ODN 15 min after cerebral ischemia sig-
nificantly reduced cerebral I/R injury via a PI3K/Akt-
dependent mechanism [80].
TLR3 ligand postconditioning and cerebral ischemic injury
For the first time, we found that the postconditioning
with the TLR3 ligand poly-IC can reduce cerebral ische-
mic injury. The intraperitoneal injection of poly-IC 3 h
after cerebral ischemia significantly reduced the volume
of cerebral infarction and the brain water content and
improved the neurological function score [92]. Poly-IC
treatment reduced the levels of TNF-α and IL-1β in the
ischemic brain tissue, cerebrospinal fluid, and peripheral
blood and increased IFN-β levels, suggesting that poly-
IC plays an important role in the protection of cerebral
ischemia by reducing the inflammatory processes. How-
ever, in TLR3-knockout mice, the protective effect of
poly-IC against cerebral ischemia disappeared. Mean-
while, our findings showed that poly-IC downregulated
the TLR4 signaling pathway and NF-κB activity in ische-
mic brain tissue, suggesting that the cerebral protective
effect of poly-IC is achieved by the downregulation of
the TLR4 signaling pathway through TLR3. Importantly,
poly-IC showed a long-term protective effect against
cerebral I/R injury as well as a protective effect against
Table 2 TLRs postconditionings and effects
Animal Model Postconditioning time/approach TLR/ischemia Results/mechanism Author References
Mice MCAO, ischemia 2 h CCA 10-s ligation, subsequently 30-s
open, a total of 3 cycles
Ischemic postconditioning Decrease brain infarction volume and improve neurological
function. Activate AKT signaling pathway
Gao X [92]
Mice MCAO, 60-min ischemia, 24-h
reperfusion
30 min/systemic injection TLR2, Pam3CSK4 Decrease brain infarction volume and improve neurological
function. Activate TLR2/PI3K/Akt signaling pathway
Lu C [65]
Mice MCAO, 60-min ischemia, 24-h
reperfusion
30 min/IP TLR3 poly-IC Decrease brain infarction and prevention of Fas/FADD
interaction
Zhang X [67]
Mice MCAO, 60-min ischemia, 48-h
reperfusion
3 h/IP TLR3 poly-IC Decrease brain infarction volume and improve neurological
function. Downregulate TLR4 signaling pathway by TLR3
Wang PF [90]
Mice MCAO, 60-min ischemia, 24-h
reperfusion
15 min/IP TLR9 CpG-ODN Decrease brain infarction and activation of PI3K/Akt Signaling Lu C [78]
MCAO: middle cerebral artery occlusion; IP: intraperitoneal injection; CCA: common carotid artery TLR: toll-like receptor; Poly-IC: polycytidylic acid; FADD: Fas-Associated protein with Death Domain; CpG-ODN: CpG-motif
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Other results showed that the therapeutic administration
of poly-IC administered 30 min after cerebral ischemia
markedly decreased infarct volume via TLR3-mediated
prevention of Fas/FADD interaction [69], suggesting that
poly-IC postconditioning plays a protective role against
cerebral I/R injuries. However, as with the concept of
TLR3 preconditioning, the concept of TLR3 postcondi-
tioning still needs to be verified.
Mechanisms for the protection of TLR postconditioning
against cerebral ischemia
The mechanism of cerebral ischemia protection by post-
conditioning is not yet fully understood. Currently, it is
generally believed that the main target of treatment after
ischemia is early reperfusion to reduce the generation of
free radicals and inflammation, reduce brain edema and
blood-brain barrier leakage, and inhibit apoptosis [93].
Moreover, the postconditioning of ischemia increased Akt
phosphorylation, and the inhibition of Akt partially weak-
ened the protective effect of the postconditioning of ische-
mia [94], suggesting that the Akt signaling pathway playsFigure 2 Poly-IC postconditioning activates the TLR3/IRF3 signaling pathw
TLR/NF-κB signaling to decrease the levels of pro-inflammatory cytokines. D
TRIF, TIR-domain-containing adapter-inducing interferon-β; IRF, interferon rean important role in the protective effect of the postcondi-
tioning. Additionally, the extracellular signal regulated
kinase (ERK) for pro-survival enzyme and the mitogen-
activated protein kinase (MAPK) also participated in the
protective effect against ischemic brain injury [91].
The protective mechanism of TLR postconditioning
against cerebral ischemia requires further investigation,
and the mechanism of TLR postconditioning is partially
similar to that of the postconditioning of ischemia. For ex-
ample, postconditioning with the TLR2 ligand Pam3CSK4
and TLR9 ligand CpG-ODN induced protection against
cerebral ischemia primarily through the PI3k/Akt signal-
ing pathway [67,80]. TLR2 can form a dimer with the PI3
enzyme to increase the activity of the P-Akt signaling
pathway and promote the anti-apoptotic effect of the cere-
bral ischemia protective agent, resulting in the cerebral
ischemia protection [67], indicating that the PI3-Akt
signaling pathway plays an important role in the brain
protection of TLR2 ligand Pam3CSK4 and TLR9 ligand
CpG-ODN postconditioning.
Our study showed that poly-IC postconditioning with
the TLR3 ligand could reduce the expression of ischemicay and increases the IFN-β levels and subsequently downregulates
AMPs, damage-associated molecular patterns; TLR, toll-like receptor;
gulatory factor; IFN, interferon; Poly-IC, polycytidylic acid.
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MyD88 signaling pathway, reduce NF-κB activity, and
reduce the production of inflammatory cytokines, such
as TNF-α and IL-β. Additionally, the downregulation of
the TLR4 signaling pathway is mediated by TLR3 [92]
(Figure 2). Additionally, the decreased cerebral I/R
injury by poly-IC via TLR3 was associated with the pre-
vention of the interaction of Fas and FADD, as well as
microglial cell caspase-3 and caspase-8 activities [69].
The clinical significance of TLR ischemic tolerance in
cerebral ischemia
In clinical practice, approximately 50% of the patients
with coronary artery bypass surgery suffer a long-term
decline in cognitive function due to the surgical complica-
tions of local or global cerebral ischemia [95]. In carotid
endarterectomy and carotid artery stent implantation, is-
chemic brain damage is a severe complication; therefore,
for these high-risk patients, a prophylactic treatment for
cerebral protection is very beneficial. Although ischemic
preconditioning can reduce the subsequent cerebral ische-
mic damage, it is difficult for high-risk patients to tolerate;
therefore, the TLR preconditioning for the protective
effect against cerebral ischemia may increasingly attract
attention. As mentioned previously, the preconditioning
of several TLR ligands significantly reduced cerebral
ischemia-reperfusion injury in mouse and rat models of
cerebral ischemia. Importantly, one study showed that the
drug preconditioning of the TLR9 ligand CpG-ODNs
could also produce a protective effect in a model of cere-
bral ischemic injury in the non-human primate rhesus
monkey, and the reagents applied in this experiment have
been used in human clinical trials, which provides a new
preventive approach for patients at high risk of cerebral
ischemia [96]. Moreover, the TLR3 ligand poly-IC has
been used as an adjuvant therapy and antitumor drug in
clinical applications [97,98], and its safety for the human
body has been confirmed, suggesting that poly-IC is a
promising precursor of the prevention drug for patients at
high risk for cerebral ischemia.
Although the preconditioning may be beneficial to
certain patients at risk of cerebral ischemia, patients
with acute stroke need an effective treatment after onset;
therefore, in recent years, increasing attention has been
focused on the postconditioning after the onset of stroke.
Postconditioning of ischemia can reduce the cerebral
edema and the leakage of the blood-brain barrier, as well
as block apoptosis by reducing the generation of free
radicals and inflammation, thereby reducing cerebral is-
chemic damage. The postconditioning of cardiac ische-
mia has been applied in clinical trials [99]. Therefore,
the cerebral ischemic tolerance induced by TLR
postconditioning provides a broad prospect of clinical
application. Ours and others’ study results showed thatpoly-IC postconditioning reduced cerebral ischemic-
reperfusion injury [69,92]; therefore, poly-IC is a promis-
ing drug precursor for the treatment of stroke. However,
the clinical trial of the TLR postconditioning for ischemic
stroke is still facing some unsolved issues, such as the
choice of the stroke patients and the effective time point
for the TLR3 postconditioning. However, although the
issues, including whether TLRs postconditioning can
extend the thrombolytic time window of r-tPA and what
the long-term effects are, urgently need to be solved,
this technique still provides a good possibility for treat-
ing ischemic stroke.
Conclusions and prospects
Cerebral ischemic injury occurs due to a series of com-
plex pathophysiological events. It has been clear that the
inflammation following ischemia mediated by TLRs
plays an important role in secondary brain injury. Inter-
estingly, the activation of TLR signals before cerebral is-
chemia can reduce the subsequent ischemic injury
caused by severe stroke, which is defined as precondi-
tioning or TLR ischemic tolerance. To date, cerebral is-
chemic damage can be reduced after the tolerance of
several TLRs was induced individually. However, the
protection mechanism of the TLR preconditioning has
not yet been fully elucidated. Currently, it is believed
that TLR preconditioning can alter TLR signaling path-
ways after ischemia, mainly manifested as the activation
of the TLR4/TRIF signaling pathway and the inhibition of
the TLR4/MyD88 signaling pathway, thereby increasing
the production of anti-inflammatory cytokines, reducing
the generation of pro-inflammatory cytokines [81], and re-
ducing the inflammatory damage of cerebral ischemia.
In recent years, postconditioning of ischemia has also
attracted attention. Our study and other studies have
shown that postconditioning with TLR2, TLR3, and TLR9
ligands could significantly reduce cerebral ischemic injury
[67,80,92], which broadens the role of TLRs in cerebral is-
chemia and provides a direction for the further research in
the protective mechanism of endogenous cerebral ischemia
induced by TLR postconditioning. Therefore, TLR postcon-
ditioning also provides a new treatment approach for ische-
mic stroke. Moreover, the TLR3 ligand poly-IC and the
TLR9 ligand CpG ODNs have been applied for other clin-
ical indications, showing significant efficacy and safety.
Therefore, treatments targeting TLRs may represent a good
prevention strategy for patients at a high risk of stroke.
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